Oncopeptides AB: Year-end Report 2018

STOCKHOLM, Feb. 22, 2019 /PRNewswire/ — Summary of Q4 Financial overview October 1 – December 31, 2018 Net sales amounted to SEK 0.0 M (0.0) Loss for the period was SEK 111.4 M (loss: 66.2) Loss per share, before and after dilution, was 2.53 (loss: 1.68) SEK On December 31 cash and cash equivalents amounted to SEK 375.6 M (404.1) Significant events during the period October 1 to December 31, 2018 At the company’s Capital Markets Day in December, an updated strategy for Oncopepti­des’ business was presented At the company’s extraordinary general meeting in December, Dr Jennifer Jackson was elected as a ...

Gepostet in der Kategorie Wirtschaft (Anzahl der ansichten:) 3

Ähnlich Nachrichten